Aldeyra received an FDA CRL for reproxalap, necessitating an additional study for DED approval. Read why I continue to rate ...
Shares of AbbVie Inc. ABBV dropped 0.43% to $170.35 Wednesday, on what proved to be an all-around positive trading session ...
Hosted on MSN4h
2 Dividend Stocks to Buy Hand Over Fist in NovemberWhich healthcare stock can dividend investors safely buy? Let's consider two excellent options: AbbVie (NYSE: ABBV) and Amgen ...
Zacks.com on MSN2h
Syros Stock Plunges as Lead Cancer Study Fails to Meet Primary GoalSYRS stock plummets as late-stage cancer study of lead candidate fails to achieve its primary endpoint leading to the termination of the study.
We read every day so you don't have to. Sign up for CNN Business' nightly newsletter for the top stories you need to know.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback